<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039038</url>
  </required_header>
  <id_info>
    <org_study_id>CURIEBOOST</org_study_id>
    <nct_id>NCT01039038</nct_id>
  </id_info>
  <brief_title>Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer</brief_title>
  <acronym>CURIEBOOST</acronym>
  <official_title>A Phase II Study Evaluating the Feasibility of a Dose Increase by a Boost of Curietherapy in PDR Associated With the Extern Radiotherapy in Intermediate Risk in the Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to evaluating the feasibility of dose increase by a boost of
      curietherapy in PDR (at least 40 Gy on D95) associated to extern radiotherapy (34 Gy) in
      intermediate risk in prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a delivered dose by a boost of curietherapy is at least 40 Gy (D95) associated to a dose of 34 Gy for extern radiotherapy</measure>
    <time_frame>at 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicities at month 3 after end of treatment: late toxicities, survival without biological relapse, without local relapse or metastatic evolution, feasibility of MRI use in prostatic CTV</measure>
    <time_frame>at 5 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer With Intermediate Risk</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>curietherapy and radiotherapy</intervention_name>
    <description>boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 50 years and ≤ 75 years

          -  Life expectancy &gt;10 years

          -  Localized prostatic adenocarcinoma and histologically proven

          -  Intermediate risk cancer(T2b or PSA between 10 and 20 or Gleason = 7(3+4) according to
             Amico criteria

          -  Metastasis or pelvic pathologic ganglion (≥ 10 mm) absence

          -  OMS &lt; 2

          -  No previous treatment by radiotherapy and/or curietherapy

          -  Hormonotherapy authorized before and during the study

          -  Rectal or uretero-vesical pathology

          -  Signed informed consent

          -  Social security system affiliation

          -  Individual deprived of liberty or placed under the authority of a tutor.

          -  No anesthesia contraindication

        Exclusion Criteria:

          -  Adenocarcinoma not histologically proven

          -  Metastases presence

          -  Pathological nodes presence(≥ 10 mm)

          -  Prior prostate endoscopic resection

          -  history of other malignancy except for appropriately treated superficial basal cell
             skin cancer

          -  Medical contraindications to anesthesia

          -  Patients with uncontrolled psychiatric disease or medical disease incompatible with
             the protocol

          -  Impossibility to respect the medical follow-up of the protocol for geographical,
             social or psychic reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <state>Basse-normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>November 24, 2011</last_update_submitted>
  <last_update_submitted_qc>November 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Anne-Catherine COURTECUISSE-DEGRENDEL</name_title>
    <organization>Centre François Baclesse</organization>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>curietherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>intermediate risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

